^
Association details:
| Biomarker: | CD19 overexpression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Published date:
11/02/2022
Excerpt:
Thirty patients were treated with niraparib and radium-223...Whole blood gene expression of PAX5 and CD19 were higher in responders and ARG-1, IL-2R and FLT3 expression were higher in non-responders.
Secondary therapy:
radium Ra-223 dichloride
DOI:
10.1158/1078-0432.CCR-22-2526
